Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of FOLFIRI plus ziv-aflibercept in previously treated metastatic colorectal cancer
jRCTs041190100Phase 2Completed
- Sponsor
- West Japan Oncology Group
- Start
- Jan 2020
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by West Japan Oncology Group. Primary endpoint: progression-free survival. Started Jan 2020; status: completed.
02
Drugs
afliberceptirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041190100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190100.